FindTrial
Sign In

A clinical trial to study efficacy of two drugs, labetalol and lignocaine in attenuating heart rate and BP in hypertensive patinets while laryngoscopy and intubation

COMPARING THE ATTENUATION OF HEMODYNAMIC RESPONSE WITH I.V LABETALOL VS I.V LIGNOGAINE IN HYPERTENSIVE PATIENTS DURING LARYNGOSCOPY AND ENDOTRACHEAL INTUBATION. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/091518
Enrollment
104
Registered
2025-07-23
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: -

Interventions

Intervention1: IV Lignocaine: The patients receive intravenous injection of 2% Lignocaine hydrochloride(without preservative) in a dose of 1.5 mg/kg before 90 seconds of laryngoscopy and intubation an

Sponsors

DR Januba S Subair
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All hypertensive patients between age of 24-80 ASA II

Exclusion criteria

Exclusion criteria: H/o chest pain/syncope/palpitations, any respiratory illness or he;antic or renal issues ASA III or more Pregnant and lactating women Morbid obesity Patient refusal

Design outcomes

Primary

MeasureTime frame
To evaluate the efficacy of 2different drugs in attenuating the hemodynamic response to laryngoscopy and intubationTimepoint: 1, 3, 5, 7 minutes—

Secondary

MeasureTime frame
IV LABETALOL is better in attenuating hemodynamic responses when compared to IVLIGNOCAINETimepoint: 1, 3, 5, 7 minutes—

Countries

India

Contacts

Public ContactDR THAMARAI SELVI

SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH

thamarai@sriramachandra.edu.in9841552333

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026